PL1629088T3 - Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje - Google Patents

Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje

Info

Publication number: PL1629088T3
Authority: PL; Poland
Prior art keywords: psca; variants; sequences; stem cell; prostate stem
Prior art date: 2003-05-30

Application number

PL04785910T

Other languages

English (en)

Inventor

Aya Jakobovits

Wangmao Ge

Arthur B Raitano

Pia M Challita-Eid

Original Assignee

Agensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-30

Filing date

2004-05-28

Publication date

2012-06-29

2004-05-28 Application filed by Agensys Inc filed Critical Agensys Inc

2012-06-29 Publication of PL1629088T3 publication Critical patent/PL1629088T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4275—Prostate specific antigen [PSA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Optics & Photonics (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Reproductive Health (AREA)
General Physics & Mathematics (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gynecology & Obstetrics (AREA)

PL04785910T 2003-05-30 2004-05-28 Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje PL1629088T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47506403P	2003-05-30	2003-05-30
PCT/US2004/017231 WO2005014780A2 (en)	2003-05-30	2004-05-28	Prostate stem cell antigen (psca) variants and subsequences thereof
EP04785910A EP1629088B1 (en)	2003-05-30	2004-05-28	Prostate stem cell antigen (psca) variants and subsequences thereof

Publications (1)

Publication Number	Publication Date
PL1629088T3 true PL1629088T3 (pl)	2012-06-29

Family

ID=34135042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04785910T PL1629088T3 (pl)	2003-05-30	2004-05-28	Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje

Country Status (23)

Country	Link
US (4)	US7622564B2 (pl)
EP (2)	EP1629088B1 (pl)
JP (1)	JP2007525196A (pl)
KR (1)	KR101291787B1 (pl)
CN (1)	CN101090729B (pl)
AT (1)	ATE541052T1 (pl)
AU (2)	AU2004263823B2 (pl)
BR (1)	BRPI0410842B8 (pl)
CA (1)	CA2526274C (pl)
CY (1)	CY1113044T1 (pl)
DK (2)	DK2319524T3 (pl)
ES (1)	ES2384622T3 (pl)
IL (1)	IL171966A (pl)
IS (1)	IS2900B (pl)
MX (1)	MXPA05012957A (pl)
NO (1)	NO20055508L (pl)
NZ (3)	NZ543840A (pl)
PL (1)	PL1629088T3 (pl)
PT (1)	PT1629088E (pl)
RU (1)	RU2005141341A (pl)
SI (1)	SI1629088T1 (pl)
WO (1)	WO2005014780A2 (pl)
ZA (1)	ZA200509606B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6541212B2 (en) *	1997-03-10	2003-04-01	The Regents Of The University Of California	Methods for detecting prostate stem cell antigen protein
US7595379B2 (en) *	2003-05-30	2009-09-29	Agensys, Inc.	Antibodies and related molecules that bind to PSCA proteins
CN101090729B (zh) *	2003-05-30	2014-07-23	艾更斯司股份有限公司	前列腺干细胞抗原(psca)变体及其序列
US7541442B2 (en) *	2003-05-30	2009-06-02	Agensys, Inc.	Antibodies and related molecules that bind to PSCA proteins
WO2006076678A2 (en) *	2005-01-13	2006-07-20	The Johns Hopkins University	Prostate stem cell antigen vaccines and uses thereof
CN101223191B (zh) *	2005-04-14	2012-09-05	阿根西斯公司	与psca蛋白结合的抗体和相关分子
US20090180958A1 (en) *	2005-04-26	2009-07-16	Karyon-Ctt Ltd.	Diagnostic and therapeutic agents
BRPI0619056A2 (pt) *	2005-11-28	2011-09-20	Genmab As	anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
WO2007086932A2 (en) *	2006-01-13	2007-08-02	The Johns Hopkins University	Prostate stem cell antigen vaccines and uses thereof
WO2007109321A2 (en)	2006-03-20	2007-09-27	The Regents Of The University Of California	Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
KR101101965B1 (ko) *	2006-10-16	2012-01-02	노키아 코포레이션	멀티뷰 비디오 코딩에 대한 병렬 디코딩가능 슬라이스들을 이용하기 위한 시스템 및 방법
WO2009032949A2 (en)	2007-09-04	2009-03-12	The Regents Of The University Of California	High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
CN101970498A (zh) *	2007-10-25	2011-02-09	维文蒂阿生物技术公司	针对变体HnRNPG的癌相关表位的抗体及其应用
US20100069616A1 (en) *	2008-08-06	2010-03-18	The Regents Of The University Of California	Engineered antibody-nanoparticle conjugates
HRP20170463T1 (hr) *	2008-11-11	2017-05-19	The Regents Of The University Of Michigan	Pripravci i postupci protiv cxcr1
WO2010096486A1 (en)	2009-02-17	2010-08-26	Cornell Research Foundation, Inc.	Methods and kits for diagnosis of cancer and prediction of therapeutic value
MX354143B (es)	2009-12-02	2018-02-14	Imaginab Inc	Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
KR101335203B1 (ko) *	2010-03-26	2013-11-29	숙명여자대학교산학협력단	혈관신생촉진용 펩타이드 및 이의 용도
US8449512B2 (en)	2010-04-09	2013-05-28	Davinci Biomedical Research Products Inc.	Stoma stabilitating device and method
AU2015261742B2 (en) *	2010-11-12	2017-10-26	Inovio Pharmaceuticals, Inc.	Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
JP6077450B2 (ja) *	2010-11-12	2017-02-08	ザトラスティーズオブザユニバーシティオブペンシルバニア	コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途
US8928126B2 (en) *	2012-11-07	2015-01-06	United Microelectronics Corp.	Epitaxial layer
EP3524262A1 (en)	2013-11-01	2019-08-14	Pfizer Inc	Vectors for expression of prostate-associated antigens
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2017141243A1 (en)	2016-02-18	2017-08-24	Enlivex Therapeutics Ltd.	Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en)	2015-02-18	2022-04-19	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en)	2015-02-18	2023-03-07	Enlivex Therapeutics R&D Ltd	Early apoptotic cells for use in treating sepsis
US11497767B2 (en)	2015-02-18	2022-11-15	Enlivex Therapeutics R&D Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en)	2015-02-18	2022-11-29	Enlivex Therapeutics Rdo Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en)	2015-02-18	2022-05-03	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en)	2015-02-18	2021-05-11	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
CN107708811B (zh)	2015-04-21	2021-04-30	恩立夫克治疗有限责任公司	治疗性汇集的血液凋亡细胞制剂与其用途
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
JP7026613B2 (ja)	2015-08-07	2022-02-28	イマジナブ・インコーポレーテッド	標的分子に対する抗原結合コンストラクト
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN106749674A (zh) *	2016-12-23	2017-05-31	四川大学	一种新型哮喘多肽疫苗及其制备方法
US11266745B2 (en)	2017-02-08	2022-03-08	Imaginab, Inc.	Extension sequences for diabodies
CN111951887B (zh) *	2020-07-27	2024-06-28	深圳市新合生物医疗科技有限公司	基于深度学习的白细胞抗原与多肽结合亲和力预测方法
CN112307622B (zh) *	2020-10-30	2024-05-17	中国兵器科学研究院	一种用于计算机生成兵力的自主规划系统及规划方法

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5736A (en)		1848-08-29		Machinery fob dressing axes
US337A (en)		1837-07-31		Mode of constructing railroad-frogs
US142A (en)		1837-03-11		Cooking apparatus
US5506A (en)		1848-04-11		Jackson stjtton
US28883A (en)		1860-06-26		James
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en)	1982-11-22	1989-09-26	The Salk Institute For Biological Studies	Method of obtaining gene product through the generation of transgenic animals
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5430136A (en)	1984-10-16	1995-07-04	Chiron Corporation	Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5124246A (en)	1987-10-15	1992-06-23	Chiron Corporation	Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en)	1987-10-15	1994-10-25	Chiron Corporation	Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
GB8724885D0 (en)	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
US5254678A (en)	1987-12-15	1993-10-19	Gene Shears Pty. Limited	Ribozymes
US5010175A (en)	1988-05-02	1991-04-23	The Regents Of The University Of California	General method for producing and selecting peptides with specific properties
CA1340323C (en)	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2049028A1 (en)	1989-03-07	1990-09-08	Genentech, Inc.	Covalent conjugates of lipid and oligonucleotide
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
WO1991006309A1 (en)	1989-11-03	1991-05-16	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
WO1991010741A1 (en)	1990-01-12	1991-07-25	Cell Genesys, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
US5204253A (en)	1990-05-29	1993-04-20	E. I. Du Pont De Nemours And Company	Method and apparatus for introducing biological substances into living cells
IE66205B1 (en)	1990-06-14	1995-12-13	Paul A Bartlett	Polypeptide analogs
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
AU8221191A (en)	1990-06-27	1992-01-23	Princeton University	Probes for detecting mutant p53
US5650489A (en)	1990-07-02	1997-07-22	The Arizona Board Of Regents	Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
SE9002480D0 (sv)	1990-07-23	1990-07-23	Hans Lilja	Assay of free and complexed prostate-specific antigen
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5541061A (en)	1992-04-29	1996-07-30	Affymax Technologies N.V.	Methods for screening factorial chemical libraries
EP0646178A1 (en)	1992-06-04	1995-04-05	The Regents Of The University Of California	expression cassette with regularoty regions functional in the mammmlian host
SG52492A1 (en)	1992-08-07	1998-09-28	Cytel Corp	Hla binding peptides and their uses
US5288514A (en)	1992-09-14	1994-02-22	The Regents Of The University Of California	Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5559410A (en)	1992-12-17	1996-09-24	Valeo Systemes D'essuyage	Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield
US5576220A (en)	1993-02-19	1996-11-19	Arris Pharmaceutical Corporation	Thin film HPMP matrix systems and methods for constructing and displaying ligands
ATE466869T1 (de)	1993-03-05	2010-05-15	Epimmune Inc	Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
CN1127527A (zh)	1993-05-17	1996-07-24	加利福尼亚大学董事会	人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
US5837501A (en)	1993-07-09	1998-11-17	Akzo Nobel N.V.	Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
AU698962B2 (en)	1993-09-14	1998-11-12	Epimmune, Inc.	Alteration of immune response using pan DR-binding peptides
US5681697A (en)	1993-12-08	1997-10-28	Chiron Corporation	Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr)	1993-12-16	1996-08-15	Maurice Stroun	Méthode pour le diagnostic de cancers.
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5593853A (en)	1994-02-09	1997-01-14	Martek Corporation	Generation and screening of synthetic drug libraries
US5539083A (en)	1994-02-23	1996-07-23	Isis Pharmaceuticals, Inc.	Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
US5525735A (en)	1994-06-22	1996-06-11	Affymax Technologies Nv	Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en)	1994-06-23	1996-08-27	Affymax Technologies Nv	Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
EP1405911A1 (en)	1994-07-20	2004-04-07	The General Hospital Corporation	Interaction trap systems for detecting protein interactions
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en)	1994-08-25	1996-12-03	Chiron Corporation	N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5681702A (en)	1994-08-30	1997-10-28	Chiron Corporation	Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en)	1994-11-09	1999-07-06	The Regents Of The University Of California	Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5962428A (en)	1995-03-30	1999-10-05	Apollon, Inc.	Compositions and methods for delivery of genetic material
CA2217545A1 (en)	1995-04-11	1996-10-17	Marc Vidal	Reverse two-hybrid systems
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
US5585639A (en)	1995-07-27	1996-12-17	Hewlett-Packard Company	Optical scanning apparatus
US5569588A (en)	1995-08-09	1996-10-29	The Regents Of The University Of California	Methods for drug screening
CU22559A1 (es)	1996-01-17	1999-05-03	Ct Ingenieria Genetica Biotech	Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
BR9708161A (pt)	1996-03-11	1999-07-27	Epimmune Inc	Peptídeos com aumentada afinidade de ligação para moléculas hla
EP0907750B1 (en)	1996-04-26	2002-09-18	Massachusetts Institute Of Technology	Three-hybrid screening assay
US5856136A (en)	1996-07-03	1999-01-05	Incyte Pharmaceuticals, Inc.	Human stem cell antigens
WO1998004720A1 (en)	1996-07-26	1998-02-05	Sloan-Kettering Institute For Cancer Research	Method and reagents for genetic immunization
US5925523A (en)	1996-08-23	1999-07-20	President & Fellows Of Harvard College	Intraction trap assay, reagents and uses thereof
US6365797B1 (en)	1997-10-15	2002-04-02	The Regents Of The University Of California	Mice models of human prostate cancer progression
EP0953039B1 (en)	1996-10-15	2007-08-29	The Regents Of The University Of California	Animal models of human prostate cancer progression
US5846722A (en)	1996-10-16	1998-12-08	Terrapin Technologies, Inc.	System to detect small molecule/peptide interaction
US5840501A (en)	1996-10-25	1998-11-24	Bayer Corporation	Determination of cPSA
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
EP0981541B1 (en)	1997-03-10	2004-06-02	The Regents Of The University Of California	Psca: prostate stem cell antigen
US6258939B1 (en) *	1997-03-10	2001-07-10	The Regents Of The University Of California	PSCA antibodies and hybridomas producing them
US6541212B2 (en) *	1997-03-10	2003-04-01	The Regents Of The University Of California	Methods for detecting prostate stem cell antigen protein
US6890749B2 (en) *	1997-05-15	2005-05-10	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
WO1998051824A1 (en)	1997-05-15	1998-11-19	Abbott Laboratories	Reagents and methods useful for detecting disease of the urinary tract
US20030044839A1 (en) *	1997-09-17	2003-03-06	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) *	1997-09-17	2002-12-19	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100502596B1 (ko) *	1997-09-17	2005-07-22	제넨테크, 인크.	분비 폴리펩티드와 막횡단 폴리펩티드 및 이들을 코딩하는핵산
EP1114152A2 (en) *	1998-09-16	2001-07-11	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883900A (en) *	1999-07-07	2001-01-30	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001040309A2 (en) *	1999-10-29	2001-06-07	Genentech, Inc.	Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6824780B1 (en) *	1999-10-29	2004-11-30	Genentech, Inc.	Anti-tumor antibody compositions and methods of use
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
AU2003234706A1 (en) *	2002-04-15	2003-11-03	Human Genome Sciences, Inc.	Antibodies that specifically bind to tl5
US7541442B2 (en) *	2003-05-30	2009-06-02	Agensys, Inc.	Antibodies and related molecules that bind to PSCA proteins
US7595379B2 (en) *	2003-05-30	2009-09-29	Agensys, Inc.	Antibodies and related molecules that bind to PSCA proteins
CN101090729B (zh) *	2003-05-30	2014-07-23	艾更斯司股份有限公司	前列腺干细胞抗原(psca)变体及其序列
HN2004000285A (es) *	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
WO2005118864A2 (en) *	2004-05-28	2005-12-15	Agensys, Inc.	Antibodies and related molecules that bind to psca proteins
WO2006112933A1 (en)	2005-04-14	2006-10-26	Agensys, Inc.	Antibodies and related molecules that bind to psca proteins
JO3421B1 (ar)	2011-06-20	2019-10-20	H Lundbeck As	طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
KR102028770B1 (ko)	2011-09-15	2019-10-04	컨버전트 인포메이션 테크놀로지스 게엠베하	로봇 프로그램의 자동 생성을 위한 시스템 및 방법
US9804664B2 (en)	2014-05-27	2017-10-31	Qualcomm Incorporated	Adaptive control of RF low power modes in a multi-rate wireless system using MCS value

2004
- 2004-05-28 CN CN200480021931.4A patent/CN101090729B/zh not_active Expired - Lifetime
- 2004-05-28 DK DK11152953.3T patent/DK2319524T3/da active
- 2004-05-28 WO PCT/US2004/017231 patent/WO2005014780A2/en not_active Ceased
- 2004-05-28 EP EP04785910A patent/EP1629088B1/en not_active Expired - Lifetime
- 2004-05-28 KR KR1020057022987A patent/KR101291787B1/ko not_active Expired - Lifetime
- 2004-05-28 NZ NZ543840A patent/NZ543840A/en not_active IP Right Cessation
- 2004-05-28 ES ES04785910T patent/ES2384622T3/es not_active Expired - Lifetime
- 2004-05-28 PT PT04785910T patent/PT1629088E/pt unknown
- 2004-05-28 SI SI200431854T patent/SI1629088T1/sl unknown
- 2004-05-28 BR BRPI0410842A patent/BRPI0410842B8/pt not_active IP Right Cessation
- 2004-05-28 PL PL04785910T patent/PL1629088T3/pl unknown
- 2004-05-28 NZ NZ578591A patent/NZ578591A/en not_active IP Right Cessation
- 2004-05-28 RU RU2005141341/15A patent/RU2005141341A/ru not_active Application Discontinuation
- 2004-05-28 NZ NZ572940A patent/NZ572940A/en not_active IP Right Cessation
- 2004-05-28 MX MXPA05012957A patent/MXPA05012957A/es active IP Right Grant
- 2004-05-28 DK DK04785910.3T patent/DK1629088T3/da active
- 2004-05-28 US US10/857,484 patent/US7622564B2/en active Active
- 2004-05-28 JP JP2006515056A patent/JP2007525196A/ja active Pending
- 2004-05-28 CA CA2526274A patent/CA2526274C/en not_active Expired - Lifetime
- 2004-05-28 EP EP11152953.3A patent/EP2319524B1/en not_active Expired - Lifetime
- 2004-05-28 AU AU2004263823A patent/AU2004263823B2/en not_active Expired
- 2004-05-28 AT AT04785910T patent/ATE541052T1/de active
2005
- 2005-11-15 IL IL171966A patent/IL171966A/en active IP Right Grant
- 2005-11-22 NO NO20055508A patent/NO20055508L/no not_active Application Discontinuation
- 2005-11-24 IS IS8148A patent/IS2900B/is unknown
- 2005-11-28 ZA ZA200509606A patent/ZA200509606B/xx unknown
2008
- 2008-12-17 AU AU2008258185A patent/AU2008258185B2/en not_active Expired
2009
- 2009-09-17 US US12/561,832 patent/US8853364B2/en not_active Expired - Lifetime
2011
- 2011-04-26 US US13/094,730 patent/US8278424B2/en not_active Expired - Lifetime
2012
- 2012-04-10 CY CY20121100353T patent/CY1113044T1/el unknown
- 2012-09-28 US US13/631,699 patent/US20130041138A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ578591A (en)	2011-01-28
NZ572940A (en)	2010-04-30
CY1113044T1 (el)	2016-04-13
EP1629088A4 (en)	2008-04-02
ES2384622T3 (es)	2012-07-10
US8853364B2 (en)	2014-10-07
IL171966A (en)	2015-09-24
ATE541052T1 (de)	2012-01-15
IS2900B (is)	2014-10-15
BRPI0410842B8 (pt)	2021-05-25
US20060029940A1 (en)	2006-02-09
BRPI0410842B1 (pt)	2019-09-24
US20110262968A1 (en)	2011-10-27
PT1629088E (pt)	2012-04-10
MXPA05012957A (es)	2006-06-27
US20100055120A1 (en)	2010-03-04
CA2526274C (en)	2015-12-01
AU2004263823A1 (en)	2005-02-17
CN101090729A (zh)	2007-12-19
US8278424B2 (en)	2012-10-02
IL171966A0 (en)	2006-04-10
RU2005141341A (ru)	2006-06-10
AU2008258185B2 (en)	2011-12-08
WO2005014780A3 (en)	2007-04-05
EP2319524A1 (en)	2011-05-11
NO20055508L (no)	2006-02-27
NZ543840A (en)	2009-09-25
NO20055508D0 (no)	2005-11-22
AU2004263823B2 (en)	2008-09-18
DK1629088T3 (da)	2012-05-07
EP2319524B1 (en)	2013-08-21
ZA200509606B (en)	2009-05-27
EP1629088A2 (en)	2006-03-01
KR101291787B1 (ko)	2013-08-07
HK1088635A1 (en)	2006-11-10
AU2008258185A1 (en)	2009-01-15
CA2526274A1 (en)	2005-02-17
DK2319524T3 (da)	2013-11-11
IS8148A (is)	2005-11-24
WO2005014780A2 (en)	2005-02-17
EP1629088B1 (en)	2012-01-11
KR20060021871A (ko)	2006-03-08
BRPI0410842A (pt)	2006-07-04
SI1629088T1 (sl)	2012-08-31
US20130041138A1 (en)	2013-02-14
JP2007525196A (ja)	2007-09-06
CN101090729B (zh)	2014-07-23
US7622564B2 (en)	2009-11-24

Publication	Publication Date	Title
PL1629088T3 (pl)	2012-06-29	Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje
WO2004016733A3 (en)	2006-03-16	Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2003040340A3 (en)	2005-04-14	Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
CY1113064T1 (el)	2016-04-13	Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 184ρ1ε2 χρησιμα στη θεραπεια και ανιχνευση καρκινου
WO2003050255A3 (en)	2005-01-06	Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
IL181218A0 (en)	2007-07-04	Nucleic acids and corresponding 58p1d12 proteins for use in the detection and treatment of cancer
WO2004098515A3 (en)	2009-04-30	Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
WO2002072785A3 (en)	2003-03-27	Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
WO2004067716A3 (en)	2006-09-28	Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2005118864A3 (en)	2006-02-09	Antibodies and related molecules that bind to psca proteins
WO2002060953A3 (en)	2003-06-26	Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
WO2006055004A8 (en)	2006-09-28	Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
WO2002092842A3 (en)	2005-04-21	Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
WO2004050828A3 (en)	2004-12-09	Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
WO2004021977A3 (en)	2004-07-22	Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
IL210928A0 (en)	2011-04-28	Antibodies specific for 238p1b2 and uses thereof
WO2002095009A3 (en)	2004-01-08	Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
DK1434592T3 (da)	2009-03-09	Nukleinsyre og tilsvarende protein med betegnelsen 121P2A3, som er anvendelige til behandling og detektion af cancer